Trial · NCT04088630
Outcomes19
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Clinically Significant Cardiac Events | up to 30 days post-ictus | All enrolled participants | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Rate of Nosocomial Infections (UTI, Sepsis, and Pneumonia) | up to 90 days post-ictus | All enrolled participants by group | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Rate of Neurologic Decline | up to 30 days post-ictus | All three arms where data were available at 90 days | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Rate of Successful Administration of Fingolimod Through an NGT or Dobhoff Tube | Enrollment | 11 subjects enrolled in open-label arm | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Percent Change in Lymphocyte Subpopulations of CD4+ T Cells | Enrollment to 30 days | Subjects where 30 day labs were obtained are included in this analysis | percent change | MEDIAN |
| SECONDARY | Percent Change in Lymphocyte Subpopulations of CD8+ T Cells | Enrollment and 30 days | Subjects where 30 day labs were obtained are included in this analysis | percent change | MEDIAN |
| SECONDARY | Percent Change in Lymphocyte Subpopulations of CD19+ B Cells | Enrollment and 30 days | Subjects where 30 day labs were obtained are included in this analysis | percent change | MEDIAN |
| SECONDARY | Change in Hematoma Volume Obtained by MRI | Enrollment and 365 days | All enrolled subjects included in analysis. Fingolimod group included 18 observations, placebo included 14 observations and open-label included 23 observations across the time period. | mm^3 per day | MEAN |
| SECONDARY | Change in Hematoma Volume Obtained by CT | Enrollment and 365 days | All enrolled subjects included in analysis. Fingolimod group included 46 observations, placebo included 39 observations and open-label included 60 observations across the time period. | mm^3 per day | MEAN |
| SECONDARY | Change in Peri-hematomal Edema Volume Obtained by CT | Enrollment to 365 days | All enrolled subjects included in analysis. Fingolimod group included 46 observations, placebo included 39 observations and open-label included 60 observations across the time period. | mm^3 | MEAN |
| SECONDARY | Change in Peri-hematomal Edema Volume Obtained by MRI | Enrollment to 365 days | All enrolled subjects included in analysis. Fingolimod group included 18 observations, placebo included 14 observations and open-label included 23 observations across the time period. | mm^3 | MEAN |
| SECONDARY | National Institutes of Health Stroke Scale Total Score (NIHSS) | 365 days | Subjects where score was collected at 365 days. | score on a scale | MEDIAN |
| SECONDARY | Interviewer-administered Modified Rankin Scale (mRS) | 365 days post-ictus | Subjects where scores were collected at 365 days. | score on a scale | MEDIAN |
| SECONDARY | Patient-Reported Outcomes Measurement Information (PROMIS) 10 Questionnaire | 365 days | Subjects completing instrument at 365 days. | score on a scale | MEDIAN |
| SECONDARY | Montreal Cognitive Assessment (MoCA) | 365 days | Subjects completing instrument at 365 days. | score on a scale | MEDIAN |
| SECONDARY | Western Aphasia Battery-Revised (WAB-R) | 365 days | Subjects completing instrument at 365 days. | score on a scale | MEDIAN |
| SECONDARY | Mortality | 30 days | All enrolled subjects | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Mortality | 90 days | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | All Cause Mortality | up to 365 days | All enrolled subjects | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04088630/outcomes